Review of the spectrum of tuberous sclerosis complex: The Saudi Arabian Experience

References

1. 1.↵
   1. O’Callaghan FJ,
   2. Shiell AW,
   3. Osborne JP,
   4. Martyn N.

   Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet (London, England) 1998; 351: 1490.

   OpenUrl
2. 2.↵
   1. Tee AR,
   2. Sampson JR,
   3. Pal DK,
   4. Bateman JM.

   The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex. Semin Cell Dev Biol 2016; 52: 12–20.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Yates JR,
   2. Maclean C,
   3. Higgins JN,
   4. Humphrey A,
   5. le Maréchal K,
   6. Clifford M, et al.

   Tuberous Sclerosis 2000 Study Group. The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management. Arch Dis Child 2011; 96: 1020–1025.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Jones AC,
   2. Shyamsundar MM,
   3. Thomas MW,
   4. Maynard, J,
   5. Idziaszczyk S,
   6. Tomkins S, et al.

   Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64: 1305–1315.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Sancak O,
   2. Nellist M,
   3. Goedbloed M,
   4. Elfferich P,
   5. Wouters C,
   6. Maat-Kievit A, et al.

   Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet 2005; 13: 731–741.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Tyburczy ME,
   2. Dies KA,
   3. Glass J,
   4. Camposano S,
   5. Chekaluk Y,
   6. Thorner AR, et al.

   Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS genetics. 2015; 11: 1–17.

   OpenUrl
7. 7.↵
   1. Northrup H,
   2. Aronow ME,
   3. Bebin EM,
   4. Bissler J,
   5. Darling TN,
   6. de Vries, PJ, et al.

   International Tuberous Sclerosis Complex Consensus Group. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 2021; 123: 50–66.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Peron A,
   2. Northrup H.

   Tuberous sclerosis complex. Am J Med Genet C Semin Med Genet 2018; 178: 274–277.

   OpenUrl
9. 9.↵
   1. Bader RS,
   2. Chitayat D,
   3. Kelly E,
   4. Ryan G,
   5. Smallhorn JF,
   6. Toi A, et al.

   Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr 2003; 143: 620–624.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Northrup H,
    2. Krueger DA

    , International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatric neurology 2013; 49: 243–254.
11. 11.↵
    1. Adriaensen ME,
    2. Schaefer-Prokop CM,
    3. Duyndam, DA,
    4. Zonnenberg BA,
    5. Prokop M.

    Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol 2011; 66: 625–628.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Au KS,
    2. Williams AT,
    3. Roach ES,
    4. Batchelor L,
    5. Sparagana SP,
    6. Delgado MR, et al.

    Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 2007; 9: 88–100.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.
    1. Numis AL,
    2. Major P,
    3. Montenegro MA,
    4. Muzykewicz DA,
    5. Pulsifer MB,
    6. Thiele EA.

    Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 2011; 76: 981–987.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Yang P,
    2. Cornejo KM,
    3. Sadow PM,
    4. Cheng L,
    5. Wang M,
    6. Xiao Y, et al.

    Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol 2014; 38: 895–909.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Holmes GL,
    2. Stafstrom CE.

    Tuberous Sclerosis Study Group. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia. 2007; 48: 617–630.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Nabbout R,
    2. Belousova E,
    3. Benedik MP,
    4. Carter T,
    5. Cottin V,
    6. Curatolo P, et al.

    TOSCA Consortium and TOSCA Investigators. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. Epilepsia open 2018; 4: 73–84.

    OpenUrl
17. 17.↵
    1. Sparagana SP,
    2. Delgado MR,
    3. Batchelor LL,
    4. Roach ES.

    Seizure remission and antiepileptic drug discontinuation in children with tuberous sclerosis complex. Arch Neurol 2003; 60: 1286–1289.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Almobarak S,
    2. Almuhaizea M,
    3. Abukhaled M,
    4. Alyamani S,
    5. Dabbagh O,
    6. Chedrawi A, et al.

    Tuberous Sclerosis Complex: Clinical Spectrum and Epilepsy: A Retrospective Chart Review Study. Transl Neurosci 2018: 9: 154–160.

    OpenUrl
19. 19.↵
    1. de Vries PJ,
    2. Whittemore VH,
    3. Leclezio L,
    4. Byars AW,
    5. Dunn D,
    6. Ess KC, et al.

    Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol 2015; 52: 25–35.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Smalley SL.

    Autism and tuberous sclerosis. J Autism Dev Disord 1998; 28: 407–414.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Vignoli A,
    2. La Briola F,
    3. Peron A,
    4. Turner K,
    5. Vannicola C,
    6. Saccani M, et al.

    Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers. Orphanet J Rare Dis 2015; 10: 1–9.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Alsowat D,
    2. Zak M,
    3. McCoy B,
    4. Kabir N,
    5. Al-Mehmadi S,
    6. Chan V, et al.

    A Review of Investigations for Patients With Tuberous Sclerosis Complex Who Were Referred to the Tuberous Sclerosis Clinic at The Hospital for Sick Children: Identifying Gaps in Surveillance. Pediatr Neurol 2020: 102: 44–48.

    OpenUrl
23. 23.
    1. Wiznitzer M.

    Autism and tuberous sclerosis. J Child Neurol 2004; 19: 675–679.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Kuzniecky RI,
    2. Jackson GD

    1. Jackson GD,
    2. Kuzniecky RI,
    3. Berkovic SF.

    CHAPTER 1 - Introduction to Epilepsy. In: Kuzniecky RI, Jackson GD, editors. Magnetic Resonance in Epilepsy. Second Edition. Burlington: Academic Press; 2005:1–16.
25. 25.↵
    1. Kwan P,
    2. Arzimanoglou A,
    3. Berg AT,
    4. Brodie MJ,
    5. Allen Hauser W,
    6. Mathern G, et al.

    Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069–1077.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Staley BA,
    2. Vail EA,
    3. Thiele EA.

    Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics 2011; 127: e117–e125.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Goh S,
    2. Kwiatkowski DJ,
    3. Dorer DJ,
    4. Thiele EA.

    Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology 2005; 65: 235–238.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Schubert-Bast S,
    2. Strzelczyk A.

    Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. Ther Adv Neurol Disord 2021; 14: 1–22.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Jacks SK,
    2. Witman PM.

    Tuberous Sclerosis Complex: An Update for Dermatologists. Pediatr Dermatol 2015; 32: 563–570.

    OpenUrl
30. 30.↵
    1. Cardis MA,
    2. DeKlotz CM.

    Cutaneous manifestations of tuberous sclerosis complex and the paediatrician’s role. Archives of disease in childhood 2017; 102: 858–863.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Cascarino M,
    2. Leclerc-Mercier S.

    Histological Patterns of Skin Lesions in Tuberous Sclerosis Complex: A Panorama. Dermatopathology (Basel) 2021; 8: 236–252.

    OpenUrl
32. 32.
    1. Shalabi D,
    2. Sethi M,
    3. Lee H,
    4. Cha J,
    5. Nikbakht N.

    Diagnosis of Tuberous Sclerosis Complex in Adulthood based on Late Presenting Cutaneous Manifestations. J Fam Med 2019; 6: 1–3.

    OpenUrl
33. 33.↵
    1. Ding Y,
    2. Wang J,
    3. Zhou H,
    4. Li T,
    5. Zhou S,
    6. Wang Y.

    Assessment of tuberous sclerosis-associated neuropsychiatric disorders using the MINI-KID tool: a pediatric case-control study. Orphanet J Rare Dis 2021; 16: 181.

    OpenUrl
34. 34.↵
    1. Toldo I,
    2. Brasson V,
    3. Miscioscia M,
    4. Pelizza MF,
    5. Manara R,
    6. Sartori S, et al.

    Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study. Dev Med Child Neurol 2019; 61: 168–173.

    OpenUrl
35. 35.↵
    1. Capal JK.

    Epilepsy and TSC-Associated Neuropsychiatric Disorders. Pediatr Neurol Briefs 2020; 34: 11.

    OpenUrl
36. 36.↵
    1. Schoenberger A,
    2. Capal JK,
    3. Ondracek A,
    4. Horn PS,
    5. Murray D,
    6. Byars AW, et al.

    Language predictors of autism spectrum disorder in young children with tuberous sclerosis complex. Epilepsy Behav 2020; 103: 1–20.

    OpenUrl
37. 37.↵
    1. Cervi F,
    2. Saletti V,
    3. Turner K,
    4. Peron A,
    5. Bulgheroni S,
    6. Taddei M, et al.

    The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1. Orphanet journal of rare diseases 2020; 15: 1–11.

    OpenUrl
38. 38.↵
    1. Frudit P,
    2. Vitturi BK,
    3. Navarro FC,
    4. Rondelli I,
    5. Pozzan G.

    Multiple cardiac rhabdomyomas in tuberous sclerosis complex: case report and review of the literature. Autops Case Rep 2019; 9: e2019125

    OpenUrl
39. 39.↵
    1. Barzegar M,
    2. Poorshiri B,
    3. Yousefi L,
    4. Raeisi S,
    5. Bakhtiary H,
    6. Eftekhari Milani A, et al.

    The clinical and paraclinical manifestations of tuberous sclerosis complex in children. Acta neurologica Belgica 2022; 122: 385–390.

    OpenUrl
40. 40.↵
    1. Hinton RB,
    2. Prakash A,
    3. Romp RL,
    4. Krueger DA,
    5. Knilans T

    , International Tuberous Sclerosis Consensus Group. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group. J Am Heart Assoc 2014; 3: 1–11.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Shiono J,
    2. Horigome H,
    3. Yasui S,
    4. Miyamoto T,
    5. Takahashi-Igari M,
    6. Iwasaki N.

    Electrocardiographic changes in patients with cardiac rhabdomyomas associated with tuberous sclerosis. Cardiol Young 2003; 13: 258–263.

    OpenUrlPubMedWeb of Science
42. 42.↵
    1. Nair N,
    2. Chakraborty R,
    3. Mahajan Z,
    4. Sharma A,
    5. Sethi SK,
    6. Raina R.

    Renal Manifestations of Tuberous Sclerosis Complex. J Kidney Cancer VHL 2020; 7: 5–19.

    OpenUrl
43. 43.↵
    1. Seyam RM,
    2. Alkhudair WK,
    3. Kattan SA,
    4. Alotaibi MF,
    5. Alzahrani HM,
    6. Altaweel WM.

    The Risks of Renal Angiomyolipoma: Reviewing the Evidence. J Kidney Cancer VHL 2017; 4: 13–25.

    OpenUrl